STAT+: Novo may be getting a better deal than expected with Medicare’s Bridge program
Novo's Medicare pricing terms and fresh evidence on stopping GLP-1 drugs both landed the same day.
TL;DR
- STAT reported that Novo may be getting a better deal than expected under Medicare's Bridge program.
- STAT also asked whether the Trump administration had just handed Novo a large financial win.
- ScienceDaily reported a study finding that stopping Ozempic may raise heart attack and stroke risk.
STAT reported that Novo may be getting a better deal than expected with Medicare's Bridge program. [1]
STAT separately examined whether the Trump administration had just cut Novo a huge financial win. [2]
ScienceDaily reported a study finding that stopping Ozempic may raise heart attack and stroke risk, evidence relevant to how patients and payers weigh continuous GLP-1 use. [3]
Why it matters
Medicare's terms for GLP-1 drugs and evidence about discontinuing them shape both Novo's revenue outlook and how payers budget for a drug class that is becoming a large recurring cost.
Editor's note
This reports pricing terms and a single study as published; it is not medical guidance and makes no recommendation about treatment.